The DynamX® Drug-Eluting Coronary Bioadaptor System is a breakthrough in percutaneous coronary intervention (PCI), uniquely designed to restore natural vessel motion and physiology after stent implantation. Unlike traditional drug-eluting stents (DES) that permanently cage the artery, DynamX® provides acute scaffolding and drug delivery, then transitions to allow the artery to regain its pulsatility, compliance, and adaptive remodeling.
Key Features & Benefits
Physiological Restoration: Restores natural vessel movement after the healing phase.
Two-Stage Design: Initial support like a DES, then uncages over time for improved vessel function.
Sirolimus Drug-Elution: Proven anti-restenotic efficacy with controlled drug release.
Biodegradable Uncaging Elements: Polymer links degrade in ~6 months to unlock the bioadaptor.
Cobalt-Chromium Helical Strands: Maintain vessel integrity while enabling motion.
Improved Clinical Outcomes: Lower target lesion failure (TLF) compared to conventional DES.
Mechanism of Action
Restore (0–6 Months)
The device acts as a DES, opening the blocked artery and releasing sirolimus to prevent restenosis.
Release (~6 Months)
Biodegradable polymer links dissolve, freeing the helical strands from their rigid “cage” configuration.
Return (6+ Months)
The artery regains its natural compliance and movement, allowing positive adaptive remodeling and improved long-term blood flow.
Clinical Evidence
BIOADAPTOR Randomized Controlled Trial: Demonstrated superior vessel physiology metrics and significantly lower late lumen loss versus Resolute Onyx DES.
2-Year Outcomes: 65% reduction in target lesion failure overall (1.9% vs. 5.5%) and 78% reduction in LAD lesions (1.9% vs. 8.7%).
Safety: No definite or probable device thrombosis reported over long-term follow-up.
| Parameter | Details |
|---|---|
| Material | Cobalt-Chromium with bioabsorbable polymer links |
| Drug | Sirolimus |
| Polymer Degradation | ~6 months |
| Vessel Compatibility | Multiple diameters and lengths available |
| Indication | Treatment of de novo coronary artery lesions |
Intended Use
The DynamX® Bioadaptor is intended to improve coronary blood flow in patients with significant coronary artery disease by providing initial vessel scaffolding, drug delivery, and subsequent restoration of natural vessel physiology.
Ordering Information
For product catalogs, technical details, and ordering inquiries, please contact our sales team at below link